DNTTIP1 promotes nasopharyngeal carcinoma metastasis via recruiting HDAC1 to DUSP2 promoter and activating ERK signaling pathway
Author:
Publisher
Elsevier BV
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference48 articles.
1. Nasopharyngeal carcinoma: an evolving paradigm;Wong;Nat Rev Clin Oncol,2021
2. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial;Mai;Nat Med,2021
3. Chemoradiotherapy improves NPC outcomes;Sidaway;Nat Rev Clin Oncol,2020
4. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as first-line therapy for recurrent or metastatic nasopharyngeal carcinoma: final overall survival analysis of GEM20110714 phase III study;Hong;J Clin Oncol,2021
5. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial;Yang;Lancet Oncol,2021
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Circulating tumor cells: from new biological insights to clinical practice;Signal Transduction and Targeted Therapy;2024-09-02
2. Histone deacetylase complexes: Structure, regulation and function;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09
3. Retinoblastoma-associated protein is important for TRIM24-mediated activation of the mTOR signaling pathway through DUSP2 action in prostate cancer;Cell Death & Differentiation;2024-03-21
4. Stable knockdown of Drp1 improves retinoic acid-BDNF-induced neuronal differentiation through global transcriptomic changes and results in reduced phosphorylation of ERK1/2 independently of DUSP1 and 6;Frontiers in Cell and Developmental Biology;2024-03-14
5. Transcription factor ATMIN facilitates chemoresistance in nasopharyngeal carcinoma;Cell Death & Disease;2024-02-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3